Immune privilege or inflammation? The paradoxical effects of fas ligand

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 2, 2000, Pages 73-79

  O'Connell, Joe ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

Apoptosis; Fas (CD95 APO 1); Fas ligand (FasL); Immune privilege; Inflammation; Transplantation

Indexed keywords

AUTACOID; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL; APOPTOSIS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; METABOLISM; NEUTROPHIL; PATHOLOGY; REVIEW;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; NEUTROPHILS; TRANSPLANTATION IMMUNOLOGY;

EID: 0033648908     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. ABREU-MARTIN M. T., VIDRICH A., LYNCH D. H. and TARGAN S. R. (1995): Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J. Immunol., 155, 4147-4154.
2. ALLISON J., GEORGIOU H. M., STRASSER A. and VAUX D. L. (1997): Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft. Proc. Natl. Acad. Sci. USA, 94, 3943-3947.
3. BATTEUX F., TOURNEUR L., TREBEDEN H., CHARREIRE J. and CHIOCCHIA G. (1999): Gene therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for FasL. J. Immunol., 162, 603-608.
4. BELLGRAU D., GOLD D., SELAWRY H., MOORE J., FRANZUSOFF A. and DUKE R. C. (1995): A role for CD95 ligand in preventing graft rejection. Nature, 377, 630-632.
5. BENNETT M. W., O'CONNELL J., O'SULLIVAN G. C., COLLINS J. K. and SHANAHAN F. (1998): Fas-mediated apoptosis in autoimmune and Helicobacter pylori-associated gastritis. Gastroenterology, 114, A930.
6. BRAUN J. S., NOVAK R., HERZOG K.-H., BODNER S. M., CLEVELAND J. L. and TOUMANEN E. I. (1999): Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med., 5, 298-302.
7. CANTWELL M. J., HUA T., ZVAIFLER N. J. and KIPPS T. J. (1997): Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum., 40, 1644-1652.
8. CHEN J.-J., SUN Y. and NABEL G. J. (1998): Regulation of the proinflammatory effects of Fas ligand (CD95L). Science, 282, 1714-1717.
9. GAINER A. L., SUAREZ-PINZON W. L., MIN W. P., SWISTON J. R., HANCOCK-FRIESEN C., KORBUTT G. S., RAJOTTE R. V., WARNOCK G. L. and ELLIOT J. F. (1998): Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation, 66, 194-199.
10. GALLE P. R., HOFMANN W. J., WALCZAK H., SCHALLER H., OTTO G., STREMMEL W., KRAMMER P. H. and RUNKEL L. (1995): Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med., 182, 1223-1230.
11. GIORDANO C., STASSI G., DE MARIA R., TODARO M., RICHIUSA P., PAPOFF G., RUBERTI G., BAGNASCO M., TESTI R. and GALLUZZO A. (1997): Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science, 275, 960-963.
12. GRIFFITH T. S., BRUNNER T., FLETCHER S. M., GREEN D. R. and FERGUSON T. A. (1995): Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270, 1189-1192.
13. GRIFFITH T. S. and FERGUSON T. A. (1997): The role of FasL-induced apoptosis in immune privilege. Immunol. Today, 18, 240-244.
14. GRIFFITH T. S., YU X., HERNDON J. M., GREEN D. R. and FERGUSON T. A. (1996): CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity, 5, 7-16.
15. HASHIMOTO H., TANAKA M., SUDA T., TOMITA T., HAYASHIDA K., TAKEUCHI E., KANEKO M., TANAKO H., NAGATA S. and OCHI T. (1998): Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum., 41, 657-662.
16. HUNT J. S., VASSMER D., FERGUSON T. A. and MILLER L. (1997): Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J. Immunol., 158, 4122-4128.
17. KANG S.-M., SCHNEIDER D. B., LIN Z., HANAHAN D., DICHEK D. A., STOCK P. G. and BAEKKESKOV S. (1997): Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med., 3, 738-743.
18. KEANE M. M., ETTENBERG S. A., LOWREY G. A., RUSSELL E. K. and LIPKOWITZ S. (1996): Fas expression and function in nor-mal and malignant breast cell lines. Cancer Res., 56, 4791-4798.
19. KORBUTT G. S., ELLIOTT J. F. and RAJOTTE R. V. (1997): Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes, 46, 317-322.
20. KROEMER G. (1997): The proto-oncogene Bcl-2 and its role in regulating apoptosis. The mechanism of action of Bcl-2 provides clues for therapeutic interventions. Nat. Med., 3, 614-620.
21. LAU H. T., YU M., FONTANA A. and STOECKERT C. J. J. (1996): Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science, 270, 109-112.
22. LI X. K., OKUYAMA T., TAMURA A., ENOSAWA S., KANEDA Y., TAKAHARA S., FUNASHIMA N., YAMADA M., AMEMIYA H. and SUZUKI S. (1998): Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation, 66, 1416-1423.
23. MITA E., HAYASHI N., IIO S., TAKEHARA T., HIJIOKA T., KASAHARA A., FUSAMOTO H. and KAMADA T. (1994): Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem. Biophys. Res. Commun., 204, 468-474.
24. MIWA K., ASANO M., HORAI R., IWAKURA Y., NAGATA S. and SUDA T. (1998): Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med., 4, 1287-1292.
25. NAGATA S. (1997): Apoptosis by death factor. Cell, 88, 355-365.
26. NOZAWA K., KAYAGAKI N., TOKANO Y., YAGITA H., OKUMURA K. and HASHIMOTO H. (1997): Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum., 40, 1126-1129.
27. O'CONNELL J., BENNETT M. W., O'SULLIVAN G. C., COLLINS J. K. and SHANAHAN F. (1997): Molecular mechanisms of Fas resistance and sensitivity of colonic epithelia. Gastroenterology, 112, A1053.
28. O'CONNELL J., BENNETT M. W., O'SULLIVAN G. C., COLLINS J. K. and SHANAHAN F. (1999): Fas counter-attack - the best form of tumor defense? Nat. Med., 5, 267-268.
29. O'CONNELL J., BENNETT M. W., O'SULLIVAN G. C., COLLINS J. K. and SHANAHAN F. (1999): The Fas counterattack: cancer as a site of immune privilege. Immunol. Today, 20, 46-52.
30. OSSINA N. K., CANNAS A., POWERS V. C., FITZPATRICK P. A., KNIGHT J. D., GILBERT J. R., SHEKHTMAN E. M., TOMEI L. D., UMANSKY S. R. and KIEFER M. C. (1997): Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem., 272, 16351-16357.
31. PETER M. E., KISCHKEL F. C., SCHEUERPFLUG C. G., MEDEMA J. P., DEBATIN K. M. and KRAMMER P. H. (1997): Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol., 27, 1207-1212.
32. RUDI J., KUCK D., STRAND S., VON HERBAY A., MARIANI S. M., KRAMMER P. H. and GALLE P. R. (1998): Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J. Clin. Invest., 102, 1506-1514.
33. SAAS P., WALKER P. R., HAHNE M., QUIQUEREZ A.-L., SCHNURIGER V., PERRIN G., FRENCH L., VAN MEIR E. G., DE TRIBOLET N., TSCHOPP J. and DIETRICH P.-Y. (1997): Fas ligand express-ion by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest., 99, 1173-1178.
34. SALMON M., SCHEEL-TOELLNER D., HUISSOON A. P., PILLING D., SHAMSADEEN N., HYDE H., DUPUY D'ANGEAC A., BACON P. A., EMERY P. and AKBAR A. N. (1997): Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest., 99, 439-446.
35. SEINO K., IWABUCHI K., KAYAGAKI N., MIYATA R., NAGAOKA I., MATSUZAWA A., FUKAO K., YAGITA H. and OKUMURA K. (1998): Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol., 161, 4484-4488.
36. SEINO K., KAYAGAKI N., OKUMURA K. and YAGITA H. (1997): Antitumor effect of locally produced CD95 ligand. Nat. Med., 3, 165-170.
37. SIOUD M., MELLBYE O. and FORRE O. (1998): Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin. Exp. Rheumatol., 16, 125-134.
38. STASSI G., TODARO M., BUCCHIERI F., STOPACCIARO A., FARINA F., ZUMMO G., TESTI R. and DE MARIA R. (1999): Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J. Immunol., 162, 263-267.
39. STRATER J., WELLISCH I., RIEDL S., WALCZAK H., KORTEZ K., TANDARA A., KRAMMER P. H. and MOLLER P. (1997): CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology, 113, 160-167.
40. STREILEIN J. W. (1995): Unraveling immune privilege. Science, 270, 1158-1159.
41. STUART P. M., GRIFFITH T. S., USUI N., PEPOSE J., YU X. and FERGUSON T. A. (1997): CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest., 99, 396-402.
42. SU X., ZHOU T., WANG Z., YANG P., JOPE R. S. and MOUNTZ J. D. (1995): Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity, 2, 353-362.
43. SUMIDA T., MATSUMOTO I., MURATA H., NAMEKAWA T., MATSUMURA R., TOMIOKA H., IWAMOTO I., SAITO Y., MIZUSHIMA Y., HASUNUMA T., MAEDA T. and NISHIOKA K. (1997): TCR in Fas-sensitive T cells from labial salivary glands of patients with Sjogren's syndrome. J. Immunol., 158, 1020-1025.
44. SWENSON K. M., KE B., WANG T., MARKOWITZ J. S., MAGGARD M. A., SPEAR G. S., IMAGAWA D. K., GOSS J. A., BUSUTTIL R. W. and SEU P. (1998): Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation, 65, 155-160.
45. TAIEB J., MATHURIN P., POYNARD T., GOUGEROT-POCIDALO M. and CHOLLET-MARTIN S. (1998): Raised plasma soluble Fas and Fas ligand in alcoholic liver disease. Lancet, 351, 1930-1931.
46. TOYOZAKI T., HIROE M., TANAKA M., NAGATA S., OHWADA H. and MARUMO F. (1998): Levels of soluble Fas ligand in myocarditis. Am. J. Cardiol., 82, 246-248.
47. ZHANG H., YANG Y., HORTON J. L., SAMOILOVA E. B., JUDGE T. A., TURKA L. A., WILSON J. M. and CHEN Y. (1997): Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest., 100, 1951-1957.
48. ZHANG L., MILLER R. G. and ZHANG J. (1996): Characterization of apoptosis-resistant antigen-specific T cells in vivo. J. Exp. Med., 183, 2065-2073.
49. ZHOU T., SONG L., YANG P., WANG Z., LUI D. and JOPE R. S. (1999): Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat. Med., 5, 42-48.